Markets

Revance's Botulinum Toxin Type A Gel in Phase II Study

An image of a stock price rising in value
Credit: Shutterstock photo

Revance Therapeutics, Inc. 's RVNC shares were up 1.6% after the company announced that it has started dosing patients with botulinum toxin type A (RT001) topical gel in a phase II study for the treatment of axillary hyperhidrosis (excessive underarm sweating).

The randomized, double-blinded, dose-ranging, placebo-controlled study will evaluate the safety and efficacy of a single, bilateral application of the candidate for the treatment of primary axillary hyperhidrosis. Interim data will be out by year end.

According to information provided by the company, approximately 9 million people are affected by hyperhidrosis in the U.S. Out of which, 50% is said to suffer from axillary hyperhidrosis. The company estimates that the worldwide potential market for treating hyperhidrosis patients with botulinum toxin had been approximately $75 million in 2014.

We note that, Revance is also studying RT001 for the treatment of lateral canthal lines, commonly known as crow's feet lines. The company plans to initiate a pivotal phase III study shortly and present results in the first half of 2016.

Meanwhile, the company continues to progress on the development of other pipeline candidates. Currently, the company is evaluating RT002 (injectable formulation of botulinum toxin type A) in a phase II study for the treatment of glabellar (frown) lines. Interim data is expected in the fourth quarter of 2015. Moreover, the company expects to initiate a phase II study on RT002 for the treatment of cervical dystonia, a muscle movement disorder, in the ongoing quarter. Preliminary data from the study is expected by the end of 2015.

Revance carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Gilead Sciences Inc. GILD , Vanda Pharmaceuticals, Inc. VNDA and Regeneron Pharmaceuticals, Inc. REGN each sporting a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

REGENERON PHARM (REGN): Free Stock Analysis Report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

VANDA PHARMACT (VNDA): Free Stock Analysis Report

REVANCE THERAP (RVNC): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

VNDA GILD REGN RVNC

Other Topics

Stocks

Latest Markets Videos